GeneDx Holdings Corp. (WGS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
GeneDx Holdings Corp. stock (WGS) is currently trading at $66.95. GeneDx Holdings Corp. PS ratio (Price-to-Sales) is 4.70. Analyst consensus price target for WGS is $156.67. WallStSmart rates WGS as Sell.
- WGS PE ratio analysis and historical PE chart
- WGS PS ratio (Price-to-Sales) history and trend
- WGS intrinsic value — DCF, Graham Number, EPV models
- WGS stock price prediction 2025 2026 2027 2028 2029 2030
- WGS fair value vs current price
- WGS insider transactions and insider buying
- Is WGS undervalued or overvalued?
- GeneDx Holdings Corp. financial analysis — revenue, earnings, cash flow
- WGS Piotroski F-Score and Altman Z-Score
- WGS analyst price target and Smart Rating
GeneDx Holdings Corp.
📊 No data available
Try selecting a different time range
Smart Analysis
GeneDx Holdings Corp. (WGS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
GeneDx Holdings Corp. (WGS) Key Strengths (3)
106.83% of shares held by major funds and institutions
Strong revenue growth at 26.50% annually
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
GeneDx Holdings Corp. (WGS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 6.6x book value
Premium valuation at 4.7x annual revenue
Supporting Valuation Data
GeneDx Holdings Corp. (WGS) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.3/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth, Market Cap. Growth metrics are encouraging with Revenue Growth at 26.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (4.70), Price/Book (6.64) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -7.60%, Operating Margin at -10.60%, Profit Margin at -4.92%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -7.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 26.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WGS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WGS's Price-to-Sales ratio of 4.70x trades at a 29% premium to its historical average of 3.64x (63th percentile). The current valuation is 70% below its historical high of 15.8x set in Nov 2025, and 15580% above its historical low of 0.03x in Apr 2023. Over the past 12 months, the PS ratio has compressed from ~8.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for GeneDx Holdings Corp. (WGS) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
GeneDx Holdings Corp. is a strong growth company balancing expansion with improving profitability. Revenue reached 428M with 27% growth year-over-year. The company is currently unprofitable, posting a -4.9% profit margin.
Key Findings
Revenue growing at 27% YoY, reaching 428M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
The company is unprofitable with a -4.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can GeneDx Holdings Corp. maintain 27%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.15, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact GeneDx Holdings Corp..
Bottom Line
GeneDx Holdings Corp. offers an attractive blend of growth (27% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About GeneDx Holdings Corp.(WGS)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.